Background: The goal of this retrospective study was to evaluate patient characteristics, treatment modalities and prognostic factors in Turkish patients with pancreatic cancer. Materials and Methods: Between January 1997 and December 2012, 64 patients who presented to the Department of Radiation Oncology, Karadeniz Technical University, Faculty of Medicine with a diagnosis of pancreatic cancer were evaluated. The E/K ratio of the cases was 2.4/1 and the median age was 59.6 (32-80) years, respectively. Some 11 cases (18%) were stage 1, 21 (34.4%) were stage 2, 10 (16.4%) were stage 3, and 19 (31.1%) were metastatic. Results: The mean follow-up time was 15.7 months (0.7-117.5) and loco-regional recurrence was noted in 11 (40.7%) who underwent surgery while metastases were observed in 41 patients (66.1%). The median overall survival (OS) was 11.2 months and the 1, 3 and 5-year OS rates were 41.7%, 9.9% and 7.9% respectively. The median disease-free survival (DFS) was 5.2 month and the1, 2 and 5 year DFS were 22.6%, 7.6% and 3.8% respectively. On univariate analysis, prognostic factors affecting OS included status of the operation (p<0.001), tumor stage (p=0.008), ECOG performance status (p=0.005) and CEA level (p=0.017).On multivariate analysis, prognostic factors affecting survival included status of the operation (p=0.033) and age (p= 0.023). Conclusions: In the current study, age and operation status were independent prognostic factors for overall survival with pancreatic patients. Thus, the patients early diagnosis and treatment ars essential. However, prospective studies with more patients are needed for confirmation.
Introduction
Pancreatic cancer is an extremely aggressive malignancy, and is the fourth most common cause of cancer-related death in the Western world. Surgical resection is the only curative option. Only 20% of patients with pancreatic cancer present at a resectable stage, 50% of these are metastatic, and 30% are at a locally advanced stage. When all stages are taken into consideration, the median survival is 5-8 months, and the 5-year survival rate is less than 5% (Barreto et al., 2007; . Poor prognosis is related to delayed diagnosis of the disease, a highly malignant potential, high rate of metastases, and high resistance to anti-tumor agents (Bayraktar et al., 2010) .
In recent years, studies have shown that the addition of chemotherapy has contributed insignificantly to survival. This has led to the investigation of new therapeutic modalities (Bramhall et al., 1995; Boeck et al., 2007; Berhard et al., 2010) . Among these new approaches, radiation therapy (RT) following systemic chemotherapy (CT) appears to be potentially useful as a treatment method (Brennan et al., 2004) . Although new developments in the , Gulsen Soydemir 1 , Zumrut Bahat 1 , Adnan Yoney 1 radiotherapy improve local control rates, systemic failure continues to be a major obstacle in improving survival (Burris et al., 1997) . In this study, patients who presented to the Department of Radiation Oncology, Karadeniz Technical University, Faculty of Medicine between January 1997 and December 2012 with a diagnosis of pancreatic cancer were studied. Treatment results and prognostic factors affecting survival were evaluated.
Materials and Methods

Patients:
In this study, 64 patients who presented to the Department of Radiation Oncology, Karadeniz Technical University, Faculty of Medicine between January 1997 and December 2012 with the diagnosis of pancreatic cancer were evaluated retrospectively. Patient information was obtained through files, conversations with patients or their relatives directly and/or by phone calls. Two patients were lost to follow-up, and one patient could not be reached. Thus, the assessment of survival was performed on 61 patients.
Staging of patients was performed in accordance with the American Joint Committee on Cancer staging system, 7th edition, 2010 TNM staging system. Performance evaluation was performed according to the Eastern Cooperative Oncology Group (ECOG).
Treatment
RT was performed between January 1997-June 2011 in a two-dimensional planning system via the Co60 and/ or linear accelerator (6-10 MV), and after June 2011 via the Linear accelerator (6-18 MV) apparatus with the threedimensional planning system. Until June 2011, anterior or posterior RT, or multi-field RT was performed at fractions of 1.8-2 Gy daily for a total of 45-50.4 Gy. After June 2011, three-dimensional conformal RT, or the IntensityModulated Radiation Therapy technique was performed at the same dose and fraction. Except for patients who were treated with palliation, the area for radiotherapy was planned to include tumor and lymphatic regions, and after exclusion of lymphatic regions over 45 Gy, Gy additional doses were administered to the tumor area. CT was then added to the treatment in various doses prior to and after radiotherapy.
Endpoints
Overall survival was defined as the duration from diagnosis to the last follow-up or date of death. Diseasefree survival was defined as the duration from the operation to recurrence or metastasis, and for inoperable patients from the date of diagnosis to metastasis.
Statistical analysis
Statistical analysis was performed with the SPSS version13 software. In order to examine the distribution of survival times, Kaplan-Meier survival analysis was used. To examine the difference in survival between groups, the log-rank test was used, and the Bonferroni correction was used to make comparisons among groups. On multivariate analysis, independent factors predicting survival were analyzed using the Cox regression analysis. A Type-1 error level of less than 5% was considered significant.
Results
Patient characteristics
Curative surgery was performed in 27 patients (43.5%) with the diagnosis of pancreatic cancer. In the study group, 35 (56.5%) patients were considered inoperable for T4 disease, metastatic involvement and poor performance status. The Whipple procedure was performed in 23 patients (85.2%) and total excision was perfomed in 4 patients (14.8%).The surgical margin was positive in 9 cases (33.3%) and negative in 17 (63%). The information about the status of surgical margins of 1 case (3.7%) could not be obtained. Patient characteristics are summarized in Table 1 .
Treatment facilities
Prior to RT, 26 (41.9%) patients underwent CT. Of these, 15 patients were (57.7%) inoperable, and 11 (42.3%) were operable. For chemotherapeutic regimens, gemcitabine was administered to 10 (38.5%) patients, while gemcitabine with cisplatin was administered to 10 (38.5%) patients, 5 FU+folinic acid was administered to 4 (15.4%) patients, and other CT regimens were administered to 2 (7.7%) patients. The number of patients who were cured from CT prior to . RT treatment was administered as part of chemoradiotherapy (CRT) in 27 of 60 patients (45%), while 8 (13.3%) underwent radical RT without CT and palliative RT was administered to 25 (41.7%) patients.
In 17 of 27 (63%) patients who underwent CRT with gemcitabine, 10 patients (37%) received 5-FU+folinic acid-based CT regimens. In patients who underwent RT, 1.8-2 Gy/day to a total 45-50.4 Gy was administered. While 21.6 Gy was given to 1 patient who subsequently died, 9 Gy was administered to 1 patient due to the deterioration of the general condition of the patient, and 36 Gy RT was administered to 1 patient due to renal toxicity. Only 15 patients (55.6%) were administered RT at 50.4 Gy. The average dose of RT in patients who underwent CRT was 45.9 Gy (9-50.4). Without addition of CT, treatment at the same dose and fraction was planned in 8 patients who underwent RT. Any patient with impaired general condition was administered 30 Gy RT. The average dose of RT in patients receiving curative RT was 47.4 (30-59.4) Gy.
With palliative RT at a fraction of 3 Gy/day, a total of 30 Gy was administered. RT was directed to the pancreatic DOI:http://dx.doi.org/10.7314/APJCP.2013.14.11 
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bed in 11 (44%) patients undergoing palliative RT, in 8 patients (32%) to the involved bones, in 4 (16%) patients to the cranium, and in 2 (8%) patients, it was directed to lung metastases. The average dose of RT in patients receiving palliative RT was 26.8 (5.4-30) Gy.
After treatment with RT, 29 (46.8%) patients received chemotherapy. 17 (58.6%) patients received gemcitabine, 6 (20.7%) patients received gemcitabine with cisplatin, 2 (6.9%) patients received 5-FU+folic acid, and 4 (13.7%) patients received other chemotherapy regimens. The average number of patients who were cured was 5.17 (1-12).
Relapsing features
The average duration of follow-up was 15.7 months (range 0.7-117.5). In 11 (40.7%) patients who underwent surgery during follow-up, local-regional recurrence was observed, and when the whole group was taken into consideration, metastases were observed in 41 (66.1%) patients. In 5 patients, (8.1%), both metastasis and recurrence were noted. The distribution of metastatic regions included the liver in 25 (60.9%) patients, bone in 11 (26.8%) patients, peritoneal carcinomatosis in 8 patients (19.5%), lung in 8 patients (19.5%), brain in 4 (9.7%) patients, and adrenal metastases in 3 (7.3%) patients (Figure 1) .
During follow-up, 56 (90.3%) patients died. The observation and treatment of 6 (9.7%)patients who survived is ongoing.
Survival
Median overall survival (OS) 11.2 months and (95%GI:9-13 .3) 1, 3 and 5 year GS are respectively, 41.7%(SE±0.064), 9.9% (SE±0.041) and 7.9% (SE±0.037) (Figure 2 ).
On univariate analysis, age (≤60 and>60), status at operation (operated with inoperable), stage (1-2, 3 and 4), gender, ECOG (0-1 and 2-3),CEA level before treatment (normal to high), CA 19-9 level before treatment (normal to high), tumor size (≤4 and >4cm), tumor location (the head-to-tail and the body), tumor grade (good, moderate and bad), nodal involvement, surgical margin status and radiation therapy (CRT with radical RT) were investigated as prognostic factors that could affect OS. Of these, operative status, stage, ECOG performance status, preoperative CEA level were statistically significant. The results of univariate analysis are summarized in Table 2 .
On multivariate analysis, age (≤60 and >60), operative status (operated with inoperable), stage (1-2, 3 and 4), gender, ECOG (0-1 and 2-3), CEA level before treatment (normal to high) were investigated as prognostic factors that could affect survival. Among these variables, the operation status [HZ: 2.4 (95%CI:1.07-5.5 GI)] (p=0.033) and age [HZ:2.6 (95%CI:1.1-6.3GI)] (p=0.023) were found to be significant. The results of multivariate analysis Table 3 . The median disease-free survival was (HS) 5.2 months (95%CI: 1.7-8 .6 GI) and the 1-2 and 5-year survival are 22.6% (SE±0.05). 7.6% (SE±0.04), and 3.8% (SE±0.03) respectively (Figure 3) .
In patients who underwent surgery, while the HS median was 8.9 months (95%GI: 2.9-15.0) in 40.1%, the 1-2 and 5-year HS was (SE±0.10), 18.1% (SE±0.08) and 9% (SE± 0.06) respectively. In inoperable patients, while the HS median was 1.5 months (95%GI: 0.0-3.9), the 1-year HS was 8.8% (SE±0.05). On univariate analysis, a statistically significant relationship (p<0.001) was found between operation status and disease-free survival. The time to recurrence and/or metastasis on average was 5.6 months (range 0-47.1).
Discussion
There is a marked increase in the incidence of pancreatic cancer (Barreto et al., 2007) . Patients with pancreatic cancer have a very poor prognosis. Although rates of 10-15% have been reported, the 5-year survival rates after resection in many centers is exceptional (Charles et al., 2005; Barreto et al., 2007) . In a review by Gudjonsson (Conlon et al., 1996) , the OS rate was reported as <0.4%, with the best overall survival rate in surgical trials being only 3.6%. However, despite high recurrence rates, surgery was identified as a factor that increased survival significantly. Other published results of the 5-year survival ranged from 5-40%, and less than 3% of patients were cured. With such a poor prognosis, it has been difficult to assess the effectiveness of therapeutic advances (Foo et al., 1993) . In our study, while the median OS was 11.2 months, the 1-2-3 and 5-year OS were found to be 41.7%, 17.8%, 9.9% and 7.9% respectively, and these rates are consistent with the literature.
Pancreatic cancer is rarely seen before the age of 45 years, and approximately 80% of the cases occur between the ages of 60 and 80 years (Garcea et al., 2008) . In our study, the median age of patients was 62 years (32-80), and this is consistent with the literature. Vainshtein et al. (Vainshtein et al., 2012) found that age was predictive of overall survival. In our study, age was found to be a prognostic factor associated with OS (p=0.023). The risk of death in patients over 60 years old was 2.6 times greater.
Worldwide, pancreatic cancer is seen more commonly in men than in women with a male/female ratio ranging from 1.5-2. However the data from England also shows that the male predominance has fallen to 1.25: 1 over the last 20 years (Bramhall et al., 1995) . In our study, the male/female ratio was 2.4/1. As stated in several studies, performance status is a well-known prognostic factor (Boeck et al., 2007; Bernhard et al., 2010) . In our study, a statistically significant difference between ECOG 0-1 and ECOG 2-3 in terms of survival (p=0.005) was noted, which is compatible with the literature.
Among pancreatic cancers, 60-70% occur at the head of the pancreas, 15-20% in the body of the pancreas, and 5-10% at the tail of the pancreas. In 16-30% of pancreatic cancers, multifocal disease is noted (Charles et al., 2005) . In our study, in 62.9% of patients, the tumor was located at the head of the pancreas, in 9.7% at the body of the pancreas, in 16.1% at the tail, and 9.7% of patients presented with multifocal disease. Although ductal epithelial cells consist of lower than 5% of pancreatic tissue, more than 90% of exocrine pancreatic cancers are adenocarcinomas originating from the ductal epithelium (Charles et al., 2005) . In our study, the histopathologic diagnosis was adenocarcinoma in 72.6% of patients.
Among other prognostic factors affecting survival in pancreatic cancer, tumor resectability, surgical margin status, and tumor stage are considered important (Evans et al., 2001; Lim et al., 2003; Brennan et al., 2004) . In our study, on univariate and multivariate analysis, a statistically significant relationship (p<0.001) was found between OS and the tumor resectability. While the median survival was 16.5 months in patients who underwent surgery, it was 7.8 months in patients who were inoperable. When the surgical margin status was assessed, it was found that the median OS in patients who had undergone surgery with positive surgical margins was 12.5 months, while the median OS was 17.5 months in those with negative surgical margins. The survival time was significantly lower in the group with positive surgical margins, although it did not reach statistically significance due to the small sample size.
The 5-year survival rates in the literature have been reported to be 31.4% at stage IA, 27.2% at stage IB, 15.7% at stage IIA, 7.7% at stage IIB, 6.8% at stage III and 2.8% at stage IV (Herreros-Villanueva et al., 2012) . While the median survival of patients with locally advanced pancreatic cancer was 6-10 months, in metastatic pancreatic cancer, the survival rate was only 3-6 months (Moertel et al., 1969; Burris et al., 1997) . In our study, the median survival was 12.5 months in patients who presented at stage 1-2, 11.2 months in patients who presented at stage 3, and 5.6 months in patients who DOI:http://dx.doi.org/10.7314/APJCP.2013.14.11.6573 Evaluation of Prognostic Factors for Pancreatic Cancer in Turkey presented at stage 4. While the 5-year survival rate for stages I-II was 16%, there were no survivors at 5 years at stages III and IV. On univariate analysis, a statistically significant relationship was found between stage and survival (p=0.008). On linear analysis, a linear relationship between stage and OS was observed (p=0.033). As the stage increased, the OS worsened. This result is consistent with the literature.
The use of CEA as a biomarker for pancreatic adenocarcinoma was investigated, but compared to CA 19-9, it was found to be less sensitive and specific for pancreatic cancer (Winter et al., 2013) . A study by Ishii et al. (1996) showed that performance status, CEA levels <10 ng/mL, and absence of distant metastases before treatment were statistically significant prognostic factors that affected survival. In this study a statistically significant relationship was found between CEA levels and survival (p=0.017).
CA 19-9 is a unique tumor marker approved by the FDA for pancreatic adenocarcinoma. It is used to determine prognosis and tumor burden (recurrence or progression) (Winter et al., 2013) . In many studies, the CA 19-9 level was included among well-known prognostic factors (Boeck et al., 2007; Bernhard et al., 2010) . However, in our study, no significant relationship between CA 19-9 levels and survival was found. The main reason for this may be low number of patients who did not undergo CA 19-9 testing.
Existing studies report local recurrence at a rate of 50-86%, and distant metastases at a rate of 40-90% after surgery (Ozaki et al., 1992; Klinkenbijl et al., 1999) . In a literature review by Garcea et al. (2008) even in the most positive subgroup with 10-15% of patients with newly diagnosed pancreatic cancer, a loco-regional recurrence rate of 50-80% and systematic failure rate of 70% has been reported. The European Study Group for Pancreatic Cancer" (ESPAC) -1 reported a local recurrence rate of 63% (Neoptolemos et al., 2004) . In a study conducted by Yovino et al. (2012) in patients with pancreatic cancer, a recurrence rate of 69% was reported in a 2-year followup period with the most common site of recurrence being the liver in 49% of patients. When the areas of treatment failure in patients with pancreatic cancer were studied, the liver and peritoneal bed after resection were the most common locations. In our study, 40.7% of patients who underwent surgery during follow-up were noted to have loco-regional recurrence. When the whole group was evaluated, the rate of metastasis was 66.1%. The most common site of metastasis was the liver in 60.9% of patients. The other metastatic sites were bone in 26.8% of patients, peritoneal carcinomatosis in 19.5%, and the lung in 19.5% of patients.
In studies involving patients who underwent curative surgery, postoperative RT and CT, a median survival of 10.9-22.7 months was reported. The 2-year survival was reported to be 18-50% (Gastrointestinal Tumor Study Group et al., 1988; Foo et al., 1993) . In patients who were inoperable and underwent RT and CT, the median survival increased from 3-6 months to 9-13 months, and the 2-year survival rates increased from 0-5% to 10-20%. In one study, while the median survival in patients who received only RT was 6 months, the survival in patients who underwent RT with 5FU chemotherapy increased to 10 months (Herreros-Villanueva et al., 2012) . Sultana et al. (2007) in their systematic review, which included a meta-analysis, showed that in locally advanced pancreatic cancer, CRT and survival increased only when compared with RT, and the risk of death was reduced by 32%. In this study, in patients who were operable and treated with CRT, the median survival was 12.5 months, while the 2-year survival was 34.4%. In patients who were operated and treated with curative RT, the median survival was 19.1 months while the 2-year survival was 50%. The median survival in patients who were inoperable and treated with CRT was 11.3 months, while the 1-year survival was 33.3%. When taking into consideration the entire sample of patients, in patients treated with CRT, the median OS was 12.4 months, and in patients receiving curative RT, the median survival was 19.1 months. The difference between the two groups was not statistically significant. Krishnan et al. (2006) reported in their study that in patients with unresectable locally advanced pancreatic cancer, the median disease-free survival was 4.2 months, and the overall survival was 8.5 months after CRT. In our study, the median HS in the whole group was 5.2 months, and the 1-2 and 5 year HS was 22.6%, 7.6% and 3.8%, respectively. On univariate analysis, a statistically significant relationship was found between operation status and disease-free survival (p<0.001).
In conclusion, over the past two decades, although several efforts have been made to study the treatment of pancreatic cancer, little benefit in survival has been achieved. After the radical resection of early-stage disease, a high rate of metastatic recurrence indicates that pancreatic cancer is a systematic disease in most patients. In the current study, age and operation status was an independent prognosis factor for overall survival with pancreatic patients. Thus, the patients early diagnosis and treatment is essential. However, due to a retrospective study, prospective studies with more patients are needed.
Furthermore, as conventional treatments have shown only a lowest impact on disease course, development of new therapeutic strategies based on the molecular biology of pancreatic cancer must be a high priority.
